A ranar 22 ga Agusta, 2025, Datopotamab deruxtecan (Dato-DXd; Datroway) ta sami amincewa a China don maganin manya marasa lafiya da ba a iya cirewa ko metastatic hormone receptor-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, ko IHC 2+/in situ hybridization [ISH] negative) waɗanda suka taɓa samun maganin endocrine da aƙalla layi ɗaya na chemotherapy a cikin yanayin ci gaba.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Wannan amincewar ta dogara ne akan sakamako mai kyau na binciken duniya na Phase III TROPION-Breast01. Binciken duniya na mataki na 3, wanda aka buga a matsayin "buɗaɗɗen lakabi", wanda aka yi a TROPION-Breast01, ya tantance antigen na saman ƙwayoyin trophoblast 2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) idan aka kwatanta da zaɓin mai bincike na chemotherapy (ICC) a cikin hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) cancer nono.
An ba marasa lafiya Dato-DXd bazuwar (n = 365) ko ICC (n = 367). Dato-DXd ya rage haɗarin ci gaba ko mutuwa sosai idan aka kwatanta da ICC (PFS ta hanyar rabon haɗarin BICR [HR], 0.63 [95% CI, 0.52 zuwa 0.76]; P < .0001). An lura da fa'idar PFS mai daidaito a cikin ƙananan ƙungiyoyi. Kodayake bayanan OS ba su cika ba, an lura da yanayin da ya fi dacewa da Dato-DXd (HR, 0.84 [95% CI, 0.62 zuwa 1.14]). Adadin abubuwan da suka faru na rashin lafiya na aji ≥3 da suka shafi magani (TRAEs) tare da Dato-DXd ya yi ƙasa da ICC (20.8% v 44.7%). Mafi yawan cututtukan TRAE (kowane mataki; mataki ≥3) sune tashin zuciya (51.1%; 1.4%) da stomatitis (50%; 6.4%) tare da Dato-DXd da neutropenia (kalmar rukuni, 42.5%; 30.8%) tare da ICC.
Marasa lafiya da suka karɓi Dato-DXd sun sami ci gaba mai mahimmanci a kididdiga a fannin PFS da kuma ingantaccen bayanin tsaro, idan aka kwatanta da ICC.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lokacin Saƙo: Agusta-26-2025